CoChat

Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis

Open access

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Interventional diagnostic and therapeutic procedures requiring intravascular iodinated contrast steadily increase patient exposure to the risks of contrast-induced acute kidney injury (CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hospitalization. The aim of this study was to investigate the efficacy of pharmacological and non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular invasive procedures with iodinated contrast. METHODS AND FINDINGS: MEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and presentations from major cardiovascular and nephrology meetings were searched, up to 22 April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI (alone or in combination) when added to saline versus each other, saline, placebo, or no treatment in patients undergoing cardiovascular invasive procedures with administration of iodinated contrast. Two reviewers independently extracted trial-level data including number of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were pooled using network meta-analysis. Treatment estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible. Saline plus N-acetylcysteine (OR 0.72, 95%CrI 0.57-0.88), ascorbic acid (0.59, 0.34-0.95), sodium bicarbonate plus N-acetylcysteine (0.59, 0.36-0.89), probucol (0.42, 0.15-0.91), methylxanthines (0.39, 0.20-0.66), statin (0.36, 0.21-0.59), device-guided matched hydration (0.35, 0.12-0.79), prostaglandins (0.26, 0.08-0.62) and trimetazidine (0.26, 0.09-0.59) were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01-0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01-0.59) were associated with lower mortality compared to saline. CONCLUSIONS: Currently recommended treatment with saline as the only measure to prevent CIAKI during cardiovascular procedures may not represent the optimal strategy. Vasodilators, when added to saline, may significantly reduce the odds of CIAKI following cardiovascular procedures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0168726

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow diagram of network meta-analysis.
Fig 1 Flow diagram of network meta-analysis.CC BY · PubMed Central
Fig 2 Network of treatment comparisons for prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular invasive procedures. The size of the nodes corresponds to the number of trials that studied the treatments. Directly compared treatments are linked with a line, the thickness of which corresponds to the number of trials that assessed the comparison. LVEDP = left ventricular end-diastolic pressure; NAC = N-acetyl cysteine; n = number of patients allocated to a specific treatment.
Fig 2 Network of treatment comparisons for prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular invasive procedures. The size of the nodes corresponds to the number of trials that studied the treatments. Directly compared treatments are linked with a line, the thickness of which corresponds to the number of trials that assessed the comparison. LVEDP = left ventricular end-diastolic pressure; NAC = N-acetyl cysteine; n = number of patients allocated to a specific treatment.CC BY · PubMed Central
Fig 3 Network meta-analysis odds ratios and 95% credible intervals for contrast-induced acute kidney injury. Comparisons between treatments should be read from left to right. Estimates of treatment effects in the cell in common between the row-defining treatment and the column-defining treatment. Odds ratios lower than 1 favour the row-defining treatment. To obtain odds ratios for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underlined. ER = event rate; LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine.
Fig 3 Network meta-analysis odds ratios and 95% credible intervals for contrast-induced acute kidney injury. Comparisons between treatments should be read from left to right. Estimates of treatment effects in the cell in common between the row-defining treatment and the column-defining treatment. Odds ratios lower than 1 favour the row-defining treatment. To obtain odds ratios for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underlined. ER = event rate; LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine.CC BY · PubMed Central
Fig 4 Forest plots for effect sizes of treatment strategies compared with saline, for mortality, dialysis, myocardial infarction and heart failure. Estimates are presented as odds ratios and 95% credible intervals (95% CrI). LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine; *in severe chronic kidney disease.
Fig 4 Forest plots for effect sizes of treatment strategies compared with saline, for mortality, dialysis, myocardial infarction and heart failure. Estimates are presented as odds ratios and 95% credible intervals (95% CrI). LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine; *in severe chronic kidney disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 38

Metadata

Authors
Navarese, E. P., Gurbel, P. A., Andreotti, F., Kołodziejczak, M. M., Palmer, S. C., Dias, S., Buffon, A., Kubica, J., Kowalewski, M., Jadczyk, T., Laskiewicz, M., Jędrzejek, M., Brockmeyer, M., Airoldi, F., Ruospo, M., De Servi, S., Wojakowski, W., O’ Connor, C., & Strippoli, G. F. M.
Affiliations
  • MultiMedica (IT)
  • Inova Fairfax Hospital (US)
  • Nicolaus Copernicus University (PL)
  • University of Otago (NZ)
  • University of Bristol (GB)
  • Antoni Jurasz University Hospital (PL)
  • Medical University of Silesia (PL)
  • Heinrich Heine University Düsseldorf (DE)
  • The University of Sydney (AU)
Corresponding author
Navarese, Eliano P.
Venue
PLOS ONE
Published
2017-02-02
Volume
12
Issue
2
Pages
e0168726
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2584407743
Cited by
38
References
41
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 11 · 2018: 4 · 2017: 3
FWCI
0.88
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Bristol Research (University of Bristol) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
  • Explore Bristol Research (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • University of Otago
  • CSL Behring
  • Regeneron Pharmaceuticals
  • National Institutes of Health
  • Medical Research Council (MR/M005232/1)
  • National Heart, Lung, and Blood Institute
  • Duke Clinical Research Institute
  • Daiichi Sankyo Europe
  • Actelion Pharmaceuticals
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
contrast-induced nephropathy, acute kidney injury prevention, iodinated contrast media, cardiovascular procedures, N-acetylcysteine, vitamin C, sodium bicarbonate, probucol, methylxanthines, statins, prostaglandins, trimetazidine, myocardial infarction, mortality, dialysis, heart failure
MeSH terms
Contrast Media, Diagnostic Techniques, Cardiovascular, Humans, Kidney Function Tests, Vasodilator Agents, Radiography, Interventional, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1371/journal.pone.0168726
The paper
Navarese, E. P., Gurbel, P. A., Andreotti, F., Kołodziejczak, M. M., Palmer, S. C., Dias, S., Buffon, A., Kubica, J., Kowalewski, M., Jadczyk, T., Laskiewicz, M., Jędrzejek, M., Brockmeyer, M., Airoldi, F., Ruospo, M., De Servi, S., Wojakowski, W., O’ Connor, C., & Strippoli, G. F. M. (2017). Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0168726

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.